Human Genome Epidemiology Literature Finder
|
Records 1 - 25 (of 25 Records) |
| Query Trace: Stomatitis and EGFR[original query] |
|---|
| Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 1 17 (5): 1131-9. Jänne Pasi A, Boss David S, Camidge D Ross, Britten Carolyn D, Engelman Jeffrey A, Garon Edward B, Guo Feng, Wong Steven, Liang Jane, Letrent Stephen, Millham Robert, Taylor Ian, Eckhardt S Gail, Schellens Jan H |
| [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2012 May 15 (5): 299-304. Li Jianjie, Qu Lili, Wei Xing, Gao Hongjun, Wang Weixia, Qin Haifeng, Tang Chuanhao, Guo Wanfeng, Wang Hong, Liu Xiaoqi |
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Sep 31 (27): 3327-34. Sequist Lecia V, Yang James Chih-Hsin, Yamamoto Nobuyuki, O'Byrne Kenneth, Hirsh Vera, Mok Tony, Geater Sarayut Lucien, Orlov Sergey, Tsai Chun-Ming, Boyer Michael, Su Wu-Chou, Bennouna Jaafar, Kato Terufumi, Gorbunova Vera, Lee Ki Hyeong, Shah Riyaz, Massey Dan, Zazulina Victoria, Shahidi Mehdi, Schuler Mart |
| Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report. Oncology letters 2013 Oct 6 (4): 1011-1014. Mekata Eiji, Endo Yoshihiro, Sonoda Hiromichi, Shimizu Tomoharu, Kawai Yuki, Umeda Tomoko, Shiomi Hisanori, Naka Shigeyuki, Kubota Yoshihiro, Murata Satoshi, Yamamoto Hiroshi, Abe Hajime, Tani Toh |
| Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted oncology 2015 Jun . Guetz Gaetan Des, Landre Thierry, Uzzan Bernard, Chouahnia Kader, Nicolas Patrick, Morere Jean-Franço |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet. Oncology 2015 Feb 16 (2): 141-51. Yang James Chih-Hsin, Wu Yi-Long, Schuler Martin, Sebastian Martin, Popat Sanjay, Yamamoto Nobuyuki, Zhou Caicun, Hu Cheng-Ping, O'Byrne Kenneth, Feng Jifeng, Lu Shun, Huang Yunchao, Geater Sarayut L, Lee Kye Young, Tsai Chun-Ming, Gorbunova Vera, Hirsh Vera, Bennouna Jaafar, Orlov Sergey, Mok Tony, Boyer Michael, Su Wu-Chou, Lee Ki Hyeong, Kato Terufumi, Massey Dan, Shahidi Mehdi, Zazulina Victoria, Sequist Lecia |
| A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors. Cancer research and treatment : official journal of Korean Cancer Association 2016 May . Han Ji-Youn, Lee Ki Hyeong, Kim Sang-We, Min Young Joo, Cho Eunkyung, Lee Youngjoo, Lee Soo-Hyun, Kim Hyae Young, Lee Geon Kook, Nam Byung Ho, Han Hyesun, Jung Jina, Lee Jin S |
| Gefitinib plus Fuzheng Kang'ai Formula () in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial. Chinese journal of integrative medicine 2017 8 24 (10): 734-740. Yang Xiao-Bing, Chai Xiao-Shu, Wu Wan-Yin, Long Shun-Qin, Deng Hong, Pan Zong-Qi, He Wen-Feng, Zhou Yu-Shu, Liao Gui-Ya, Xiao Shu-Ji |
| Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung cancer (Amsterdam, Netherlands) 2017 04 106 76-82. Kim Dong-Wan, Garon Edward B, Jatoi Aminah, Keefe Dorothy M, Lacouture Mario E, Sonis Stephen, Gernhardt Diana, Wang Tao, Giri Nagdeep, Doherty Jim P, Nadanaciva Sashi, O'Connell Joseph, Sbar Eric, Cho Byoung Ch |
| Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer research and treatment 2017 Jan . Lee Youngjoo, Lee Ki Hyeong, Lee Geon Kook, Lee Soo-Hyun, Lim Kun Young, Joo Jungnam, Go Yun Jung, Lee Jin Soo, Han Ji-Yo |
| Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. OncoTargets and therapy 2018 12 11 8575-8587. Wu Yi-Long, Xu Chong-Rui, Hu Cheng-Ping, Feng Jifeng, Lu Shun, Huang Yunchao, Li Wei, Hou Mei, Shi Jian Hua, Märten Angela, Fan Jean, Peil Barbara, Zhou Caic |
| Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2018 12 31 (5): 380-383. ?oupková Helena, Vyzula Rostisl |
| EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC cancer 2019 Jun 19 (1): 595. Fang Wenfeng, Huang Yihua, Hong Shaodong, Zhang Zhonghan, Wang Minghui, Gan Jiadi, Wang Wenjing, Guo Honglin, Wang Kai, Zhang |
| Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. International journal of clinical oncology 2019 4 24 (8): 917-926. Tamura Kazuo, Nukiwa Toshihiro, Gemma Akihiko, Yamamoto Nobuyuki, Mizushima Masaya, Ochai Kaori, Ikeda Rie, Azuma Hisaya, Nakanishi Yoic |
| [EGFR-TKI ADR Management Chinese Expert Consensus]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2019 3 22 (2): 57-81. Authors are not available |
| The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of Cancer 2019 3 10 (4): 885-892. Wang Chi, Li Yun, Ke Li, Cao Lejie, Fan Pingsheng, Wu Zhiwei, Wu Qu |
| Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs 2020 12 81 (2): 257-266. Mok Tony S, Cheng Ying, Zhou Xiangdong, Lee Ki Hyeong, Nakagawa Kazuhiko, Niho Seiji, Chawla Alka, Rosell Rafael, Corral Jesus, Migliorino Maria Rita, Pluzanski Adam, Noonan Kay, Tang Yiyun, Pastel Malaika, Wilner Keith D, Wu Yi-Lo |
| Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events. Journal of oncology 2021 7 2021 2414897. Logan Jessica M, Brooks Doug A, Rowland Andrew, Sorich Michael J, Hopkins Ashley |
| Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations. Translational lung cancer research 2021 2 10 (1): 183-192. Ko Ryo, Shukuya Takehito, Imamura Chiyo K, Tokito Takaaki, Shimada Naoko, Koyama Ryo, Yamada Kazuhiko, Ishii Hidenobu, Azuma Koichi, Takahashi Kazuhi |
| FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 9 29 (3): 508-512. Duke Elizabeth S, Stapleford Liza, Drezner Nicole, Amatya Anup K, Mishra-Kalyani Pallavi S, Shen Yuan-Li, Maxfield Kimberly, Zirkelbach Jeanne Fourie, Bi Youwei, Liu Jiang, Zhang Xinyuan, Wang Hezhen, Yang Yuching, Zheng Nan, Reece Kelie, Wearne Emily, Glen Jacqueline J, Ojofeitimi Idara, Scepura Barbara, Nair Abhilasha, Bikkavilli Rama Kamesh, Ghosh Soma, Philip Reena, Pazdur Richard, Beaver Julia A, Singh Harpreet, Donoghue Mart |
| Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jun OF1-OF10. Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
| Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 5 . Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
| Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Acta oncologica (Stockholm, Sweden) 2022 10 61 (11): 1347-1353. Li Li, Huang Qin, Sun Jianhai, Yan Fei, Wei Wujie, Li Zihui, Liu Li, Deng J |
| A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations. Lung cancer (Amsterdam, Netherlands) 2023 8 184 107349. Takashi Ninomiya, Nobuhisa Ishikawa, Toshiyuki Kozuki, Shoichi Kuyama, Koji Inoue, Toshihide Yokoyama, Nobuhiro Kanaji, Masayuki Yasugi, Takuo Shibayama, Keisuke Aoe, Nobuaki Ochi, Kazunori Fujitaka, Masahiro Kodani, Yutaka Ueda, Kazuhiko Watanabe, Akihiro Bessho, Keisuke Sugimoto, Isao Oze, Katsuyuki Hotta, Katsuyuki Kiu |
| Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation: A multicenter, case-series study in China. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2024 9 36 (4): 398-409. Shouzheng Wang, Jiayu Liu, Yan Wang, Ying Hu, Ziling Liu, Yu Yao, Li Liang, Yutao Liu, Lin Wang, Junling Li, Puyuan Xi |
- Page last reviewed:Feb 1, 2024
- Content source: